References
- NorrisL, JoyceM, O'KeeffeN, SheppardJ, BonnarJ. Haemostatic risk factors on healthy postmenopausal women taking hormone replacement therapy. Maturitas 2002;43:125–133.
- FarquharC, MarjoribanksJ, LethabyA, SucklingJA, LambertsQ. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009;2:CD004143.
- WolfangJ, El-SamaloutiV, GerlingerC, SchaefersM. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weght: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethsterone acetate. Eur J Obstet Gynecol Reprod Biol 2009;147:195–200.
- SandsetP, HoibraatenE, EilertsenA, DahmA. Mechanisms of thrombosis related to hormone therapy. Thromb Res 2009;123:70–73.
- MillerVM, JayachandranM, HeitJA, OwenWG. Estrogen therapy and thrombotic risk. Pharmacol Ther 2006;111:792–807.
- NorrisLA, BrosnanJ, BonnarJ, ConardJ, KluftC, HellgrenM. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/dydrogesterone and estradiol (2 mg)/trimegestone. Thromb Haemost 2008;100:253–260.
- SimomciniT, MannellaP, GenazzaniAR. When hormone therapy sneaks under your nose. Menopause 2008;15:215–216.
- CellejonD, FranceschiniA, MontesM, ToloiM. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women. Maturitas 2005;52:249–255.
- ScarabinPY, OgerE, Plu-BureauG. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–432.
- Koh S CL, DramuscV, RatnamS. The effects of long-term hormone-replacement therapy on coagulation, fibrynolysis and inhibitors in postmenopausal women. Int J Gynecol Obstet 1998;62:279–285.
- KostkaB, ParaJ, SikoraJ. A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening. Blood Coagul Fibrinol 2007;18:611–618.
- NozakiM, OgataR, KoeraK, HashimotoK, NakanoH. Changes In coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy. Climacteric 1999;2:124–130.
- JickH, DerbyLE, MyersMW. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981–983.
- GrodsteinF, StampferMJ, GoldhaberSZ. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983–987.
- DalyE, VesseyMP, HawkinsMM. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977–980.
- CanonicoM, StraczekC, OgerF. Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings. Maturitas 2006;54:372–379.
- StraczekC, OgerE, Yon de Jonage-CanonicoMB. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495–3500.
- SchaudigK, TnomssenC. Hormonal therapy with patch or pill: How does it matter? Thromb Haemost 2007;97:503–504.
- KosterT, RosendaalFR, ReitsmaPH, van der VeldenPA, BrietE, VandenbrouckeJP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case–control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994;71:719–722.
- Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, Visser J, Stamer S, Liebler DC, Koliakos G, Heijnen HF, et al. Fibrinogen β-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem 2008;283:33846–33853.
- ZeguraB, Guzic-SalabirB, SebestejenM, KeberI. The effect of various manopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postemopausal women. Menopause 2006;13:643–650.
- VehkavaaraS, SilveiraA, Hakala-AlaPT. Effects of oral and transdermal estrogen repalcement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postemopausal women. Thromb Haemost 2001;85:619–625.
- BrosnanJ, SheppardB, NorrisLA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost 2007;97:558–565.
- BarczyńskiB., KotarskiJ. Hormonal therapy and thromboembolic disease. Przegląd Menopauzalny 2008;3:127–131.